← Back to Search

CAR T-cell Therapy

Dose Level -1 for HIV

Q: Are there any available positions for patients to participate in this clinical trial?

<p>Clinicaltrials.gov data indicates that the recruitment for this particular trial is currently closed. The trial was initially listed on March 30, 2024 and last revised on February 1, 2024. Despite this study being inactive in terms of participant enrollment, there are nine ongoing clinical trials actively seeking eligible individuals to join their research endeavors.</p>

Phase < 1

Waitlist Available

Led By John H. Baird, MD

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participant must be ≥ 18 years of age at the time of screening

Karnofsky Performance Status (KPS) ≥ 70

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days after the infusion

Awards & highlights

Study Summary

"This trial aims to use engineered T cells to target and eliminate HIV-infected cells in individuals living with HIV. The study will investigate the use of cytomegalovirus-specific T cells to enhance the

Who is the study for?

This trial is for people living with HIV who are on anti-retroviral therapy (ART) but still have the virus in their bodies. Participants should be generally healthy and have a history of cytomegalovirus (CMV), which most HIV-positive individuals do.Check my eligibility

What is being tested?

The study is testing CMV/HIV-CAR T Cells, a type of immunotherapy designed to target and destroy HIV-infected cells using the body's own modified T cells that can also respond to CMV, potentially leading to long-term remission of HIV.See study design

What are the potential side effects?

Potential side effects may include immune reactions from the engineered T cells, such as fever or fatigue. There could also be risks associated with infusing these modified cells into the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am mostly able to care for myself.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days after the infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days after the infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days after the infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicities (DLT)

Toxicity profile

Secondary outcome measures

CD4+ T cell count and HIV RNA levels

Cytokine levels

EGFR+ CD3+ T cells

+1 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: Dose Level -1Experimental Treatment1 Intervention

EGFR+ T Cell Dose (Day 0) 5 x 10^6 cells

Group II: Dose Level +2Experimental Treatment1 Intervention

EGFR+ T Cell Dose (Day 0) 50 x 10^6 cells

Group III: Dose Level +1Experimental Treatment1 Intervention

EGFR+ T Cell Dose (Day 0) 25 x 10^6 cells

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor

565 Previous Clinical Trials

1,921,445 Total Patients Enrolled

John H. Baird, MDPrincipal InvestigatorCity of Hope Medical Center

David (Davey) Smith, MDPrincipal InvestigatorUCSD, San Diego Center for AIDS Research

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available positions for patients to participate in this clinical trial?

"Clinicaltrials.gov data indicates that the recruitment for this particular trial is currently closed. The trial was initially listed on March 30, 2024 and last revised on February 1, 2024. Despite this study being inactive in terms of participant enrollment, there are nine ongoing clinical trials actively seeking eligible individuals to join their research endeavors."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

2024. "CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06252402.

All > Cmv > Aids